At a glance
ClinicalIndex Comparison Record- ✓Perihilar cholangiocarcinoma (pCCA) confirmed by positive/suspicious intraluminal brush cytology/biopsy, or radiographic malignant stricture with CA 19-9 >100 U/ml, polysomy on FISH, or well-defined mass
- ✓Single tumor mass
- ✓Unresectable tumor or patient deemed unfit for surgery
- ✓TNM staging: T1-T4, N0-N1-N2, M0 (AJCC 8th edition)
- ✕Prior liver surgery or transplantation
- ✕Tumor extension into stomach, colon, duodenum, pancreas, or abdominal wall
- ✕Ascites present
- ✕Prior radiotherapy to the liver
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: A Multicenter Phase II Trial (The STRONG 2 Trial)
In Brief
A clinical study evaluating Stereotactic body radiation therapy for Klatskin Tumor. Currently recruiting, targeting 30 participants across 8 sites in 2 countries.
Detailed Summary
The objective of this study is to evaluate the efficacy of stereotactic body radiation therapy (SBRT) as additional treatment after standard chemotherapy regarding tumor local control, toxicity, progression-free survival (PFS), overall survival and quality of life. In addition, the objective is to explore the value of immunodynamics in peripheral blood for predicting PFS in patients undergoing chemotherapy.
Study Details
Timeline
Interventions
SBRT will be delivered in 15 fractions of 4 to 4.5Gy (risk-adapted), one fraction each weekday for 3 weeks.